Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

ProQR Therapeutics NV (0PQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.7870 -0.0480    -2.62%
07:05:10 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 1.7550 / 1.8010
  • Day's Range: 1.7870 - 1.7870
Type:  Equity
Market:  Germany
ISIN:  NL0010872495 
S/N:  A12B97
ProQR Therapeutics NV 1.7870 -0.0480 -2.62%

ProQR Therapeutics NV Company Profile

 
Read the ProQR Therapeutics NV company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Contact Information

Address Zernikedreef 9
Leiden, 2333 CK
Netherlands
Phone 31 88 166 7000
Fax -

Top Executives

Name Age Since Title
Donald S. Fong - 2020 Member of Scientific Advisory Board
Bart Filius 51 2019 Independent Supervisory Board Member
James S. Shannon 65 2016 Independent Member of Supervisory Board & Chairman of Scientific Advisory Board
Domenico Valerio 66 2014 Founder & Independent Chairman of Supervisory Board
Arthur A. Levin 69 - Member of Scientific Advisory Board
Alison F. Lawton 62 2014 Independent Member of Supervisory Board
Theresa Marie Heggie 63 2021 Supervisory Board Member
Phillip D. Zamore - 2017 Member of Scientific Advisory Board
Peter A. Beal - 2018 Member Scientific Advisory Board
Yi-Tao Yu - 2018 Member of Scientific Advisory Board
Martin A. Maier - 2020 Member of Scientific Advisory Board
Begona Carreno - 2023 Supervisory Board Member
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PRQR Comments

Write your thoughts about ProQR Therapeutics NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email